4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 10% – Time to Buy?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s share price was up 10% during trading on Monday . The company traded as high as $13.15 and last traded at $13.4030. 182,547 shares were traded during trading, a decline of 77% from the average daily volume of 783,342 shares. The stock had previously closed at $12.19.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. B. Riley Financial began coverage on 4D Molecular Therapeutics in a report on Friday, July 31st. They issued a “buy” rating and a $37.00 price target for the company. The Goldman Sachs Group reaffirmed a “buy” rating and set a $32.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday. Chardan Capital raised 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $29.62.

4D Molecular Therapeutics Stock Up 14.7%

The firm has a 50-day moving average of $10.94 and a two-hundred day moving average of $9.89. The firm has a market capitalization of $730.82 million, a PE ratio of -5.34 and a beta of 2.73. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). The business had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. On average, equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.88 EPS for the current year.

Insider Buying and Selling

In related news, insider David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $10.05, for a total value of $124,770.75. Following the completion of the sale, the insider owned 871,737 shares in the company, valued at approximately $8,760,956.85. The trade was a 1.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the transaction, the insider owned 8,617 shares of the company’s stock, valued at $103,404. This trade represents a 53.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 197,226 shares of company stock valued at $2,200,677 in the last three months. Corporate insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Persistent Asset Partners Ltd bought a new stake in shares of 4D Molecular Therapeutics during the 2nd quarter worth about $1,936,000. Dimensional Fund Advisors LP raised its stake in shares of 4D Molecular Therapeutics by 77.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company’s stock worth $4,863,000 after buying an additional 227,982 shares in the last quarter. Exome Asset Management LLC acquired a new stake in shares of 4D Molecular Therapeutics in the first quarter valued at $1,216,000. Evergreen Quality Fund GP Ltd. acquired a new stake in shares of 4D Molecular Therapeutics in the fourth quarter valued at $7,136,000. Finally, Simplify Asset Management Inc. bought a new position in 4D Molecular Therapeutics during the first quarter valued at about $656,000. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.